{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:33:56Z","timestamp":1793093636558,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"TenNor Therapeutics Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.diagmicrobio.2020.115040","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T23:52:25Z","timestamp":1584575545000},"page":"115040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["In vitro activity of TNP-2092 against periprosthetic joint infection\u2013associated staphylococci"],"prefix":"10.1016","volume":"97","author":[{"given":"Cody R.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzannah M.","family":"Schmidt-Malan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenkun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0005","doi-asserted-by":"crossref","first-page":"e00959","DOI":"10.1128\/AAC.00959-19","article-title":"In vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against planktonic and biofilm states of staphylococci isolated from periprosthetic joint infection","volume":"63","author":"Albano","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0010","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ijantimicag.2007.07.011","article-title":"Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA)","volume":"30","author":"Appelbaum","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0015","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1128\/AAC.42.10.2590","article-title":"Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus","volume":"42","author":"Aubry-Damon","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0020","first-page":"6","article-title":"In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates","volume":"148","author":"Ben","year":"2018","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0025","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/JCM.37.6.1771-1776.1999","article-title":"The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms","volume":"37","author":"Ceri","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0030","series-title":"Methods for determining bactericidal activity of antimicrobial agents; approved guideline M26-A","author":"Clinical and Laboratory Standards Institute","year":"1999"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0035","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 11th ed. CLSI standard M07","author":"Clinical and Laboratory Standards Institute","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0040","series-title":"29th ed CLSI supplement M100 Wayne","article-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0045","series-title":"TNP-2092 to treat acute bacterial skin and skin structure infection (P2_ABSSSI) \u2014 identifier: NCT03964493","author":"ClinicalTrials.gov","year":"2019"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1874285801307010059","article-title":"Multidrug efflux pumps in Staphylococcus aureus: an update","volume":"7","author":"Costa","year":"2013","journal-title":"Open Microbiol J"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0055","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jac\/19.3.313","article-title":"Comparative in-vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM427, against Staphylococcus aureus","volume":"19","author":"der Auwera","year":"1987","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0060","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2174\/1568026616666160927150839","article-title":"Multi-target directed indole based hybrid molecules in cancer therapy: an up-to-date evidence-based review","volume":"17","author":"Dhanya","year":"2017","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/13543784.2017.1304538","article-title":"Cadazolid for the treatment of Clostridium difficile","volume":"26","author":"Endres","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.micpath.2017.08.026","article-title":"Frequency of efflux pump genes mediating ciprofloxacin and antiseptic resistance in methicillin-resistant Staphylococcus aureus isolates","volume":"111","author":"Hassanzadeh","year":"2017","journal-title":"Microb Pathog"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0075","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1128\/AAC.38.12.2702","article-title":"Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model","volume":"38","author":"Kang","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0080","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000339861","article-title":"Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol","volume":"90","author":"Knorr","year":"2012","journal-title":"Pharmacology"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0085","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1021\/acs.jmedchem.6b00485","article-title":"Development of a dual-acting antibacterial agent (TNP-2092) for the treatment of persistent bacterial infections","volume":"59","author":"Ma","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0090","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1051\/sicotj\/2016038","article-title":"The DAIR (debridement, antibiotics and implant retention) procedure for infected total knee replacement \u2014 a literature review","volume":"3","author":"Qasim","year":"2017","journal-title":"SICOT-J"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0095","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1128\/AAC.01651-07","article-title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci","volume":"52","author":"Robertson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0100","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1128\/AAC.01649-07","article-title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus","volume":"52","author":"Robertson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2016.01.008","article-title":"In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections","author":"Schmidt-Malan","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0110","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1016\/j.bmc.2017.02.068","article-title":"Covalently linked kanamycin \u2014 ciprofloxacin hybrid antibiotics as a tool to fight bacterial resistance","volume":"25","author":"Shavit","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.diagmicrobio.2020.115040_bb0115","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/CMR.00111-13","article-title":"Prosthetic joint infection","volume":"27","author":"Tande","year":"2014","journal-title":"Clin Microbiol Rev"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319307229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319307229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:53:54Z","timestamp":1760003634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889319307229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0732889319307229"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115040","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of TNP-2092 against periprosthetic joint infection\u2013associated staphylococci","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115040"}}